| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 146, 1199-1206, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
NA Gruis, J Weaver-Feldhaus, Q Liu, C Frye, R Eeles, I Orlow, L Lacombe, V Ponce- Castaneda, P Lianes and E Latres
Myriad Genetics, Inc., Salt Lake City, UT 84108, USA.
The 9p21 region of human chromosome 9 is a hot spot for chromosomal aberrations in both cultured cell lines and primary tumors. This region contains a gene, P16 (also called MTS1, CDKN2 and p16INK4), that encodes a presumptive negative cell cycle regulator called p16. P16 is deleted or mutated at high frequency in a variety of tumor cell lines including melanoma and bladder carcinoma lines. As such, it is likely to be a tumor suppressor gene. Here we show that P16 is mutated in primary bladder carcinomas (3 of 33) and melanomas (5 of 34). These findings support studies that show P16 mutations are not solely a product of growth in tissue culture but rather are involved in formation of tumors in viva. Some bladder primary tumors and some bladder and melanoma tumor cell lines contain mutations in both P16 and P53 at frequencies that suggest that p53 and p16 function in different pathways, each of which is important in suppressing malignant transformation.
This article has been cited by other articles:
 |
|
 |
|
  D. E. Freedberg, S. H. Rigas, J. Russak, W. Gai, M. Kaplow, I. Osman, F. Turner, J. A. Randerson-Moor, A. Houghton, K. Busam, et al. Frequent p16-Independent Inactivation of p14ARF in Human Melanoma J Natl Cancer Inst, June 4, 2008; 100(11): 784 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. A.-E. Hussein and G. S. Wood Molecular Aspects of Melanocytic Dysplastic Nevi J. Mol. Diagn., May 1, 2002; 4(2): 71 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Orlow, P. Roy, A. Barz, R. Canchola, Y. Song, and M. Berwick Validation of Denaturing High Performance Liquid Chromatography as a Rapid Detection Method for the Identification of Human INK4A Gene Mutations J. Mol. Diagn., November 1, 2001; 3(4): 158 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Pollock, J. Welch, and N. K. Hayward Evidence for Three Tumor Suppressor Loci on Chromosome 9p Involved in Melanoma Development Cancer Res., February 1, 2001; 61(3): 1154 - 1161. [Abstract] [Full Text]
|
|
|
|
|
|
N. Soufir, L. Daya-Grosjean, P. de La Salmoniere, J.-P. Moles, L. Dubertret, A. Sarasin, and N. Basset-Seguin Association Between INK4a-ARF and p53 Mutations in Skin Carcinomas of Xeroderma Pigmentosum Patients J Natl Cancer Inst, November 15, 2000; 92(22): 1841 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Cachia, J. O. Indsto, K. M. McLaren, G. J. Mann, and M. J. Arends CDKN2A Mutation and Deletion Status in Thin and Thick Primary Melanoma Clin. Cancer Res., September 1, 2000; 6(9): 3511 - 3515. [Abstract] [Full Text]
|
|
|
|
|
|
O. Straume, L. Sviland, and L. A. Akslen Loss of Nuclear p16 Protein Expression Correlates with Increased Tumor Cell Proliferation (Ki-67) and Poor Prognosis in Patients with Vertical Growth Phase Melanoma Clin. Cancer Res., May 1, 2000; 6(5): 1845 - 1853. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Papp, H. Pemsel, R. Zimmermann, R. Bastrop, D. G Weiss, and D. Schiffmann Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi J. Med. Genet., August 1, 1999; 36(8): 610 - 614. [Abstract] [Full Text]
|
|
|
|
|
|
Z.-T. Zhang, J. Pak, E. Shapiro, T.-T. Sun, and X.-R. Wu Urothelium-specific Expression of an Oncogene in Transgenic Mice Induced the Formation of Carcinoma in Situ and Invasive Transitional Cell Carcinoma Cancer Res., July 1, 1999; 59(14): 3512 - 3517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chin, G. Merlino, and R. A. DePinho Malignant melanoma: modern black plague and genetic black box Genes & Dev., November 15, 1998; 12(22): 3467 - 3481. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
